Conigen News and Events
What’s New at Conigen: Expanded Custom Recombinant Protein and Antibody Services
As part of our commitment to supporting discovery with high-quality, native-like proteins, Conigen has expanded its custom protein expression and antibody solutions. These services are built on our proprietary technology platforms and decades of applied experience in protein expression, antibody generation, and functional validation.
We offer a modular, milestone-driven workflow with standardized quality control checkpoints—allowing our clients to scale up with confidence and receive project-ready functional recombinant proteins or high purity and specificity recombinant or monoclonal antibodies .
Expanded Custom Recombinant Protein and Antibody Development for Drug Discovery:
Custom Conformational Protein Expression
- Design and expression of soluble or full-length membrane proteins
- Proprietary cis-dimer motif with stabilization domains
- Optimized for native-like structure and functional bioactivity
- Deliverable: Validated protein (milligram quantities) and project data report
- Learn about single-pass ectodomain soluble proteins: CD3 epsilon/delta, IL-2Rb/g
- View multi-pass membrane associated proteins: Claudin 6, Claudin 9, CXCR4
Recombinant Antibody Expression in HEK293 Cells
- Production of target-specific antibody plasmids (heavy and light chains)
- Expression yields suitable for screening and characterization
- Deliverable: Milligram quantities of purified antibody and data report
Mouse Monoclonal Antibody (mAb) Development
- Custom immunization strategies (membrane targets, weak immunogens)
- High-affinity mAbs generated via hybridoma technology
- Deliverable: Clonal hybridoma lines and 1 mg purified mAb and data report
Why It Matters
Nature doesn’t compromise on structure. Neither do we.
Conigen’s recombinant protein platforms solve persistent bottlenecks in discovery by recreating the structural context that proteins require for biological activity. Whether you’re screening therapeutic antibodies, testing drug-receptor interactions, or designing immunogens, functionally validated, native-like proteins reduce false positives and speed up validation.
- Bioactivity confirmed through ELISA, flow cytometry, or ligand-binding assays
- Broader screening windows than monomers
- Reduced need for re-screening and troubleshooting
From Concept to Confidence
Every custom project at Conigen is guided by a foundational belief: the closer we mimic nature, the more reliable the research outcome.
Whether you’re working on antibody discovery, immune profiling, or therapeutic target validation, our platforms are designed to increase efficiency without compromising structural integrity. We don’t just deliver materials — we deliver confidence in the form of bioactive, native-like molecules that perform as expected.
What’s New at Conigen: Conformational Recombinant Proteins with New Data, New Insights — See Us at AAI 2025 and PEGS
In addition to expanding our portfolio of recombinant proteins that mimic nature, Conigen scientists will be presenting new data at two leading scientific conferences this May, AAI 2025 (booth #539) in Honolulu and PEGS (booth #511) in Boston.
Our posters focus on improving binding affinity, epitope accessibility, and recombinant protein formats for difficult-to-express targets like GPCRs, cytokine receptors, and immune co-stimulatory molecules.
AAI 2025
| Chemokine receptors CXCR4 or CXCR5 displayed on nanoparticles are bioactive and able to bind its relevant ligand CXCL12 or CXCL13 Poster #406 Focus: Functional validation of full-length GPCRs in VLP format |
| Engineered novel cytokine receptors IFNγR1, IL10Rα and IFNαR1/2 cis-dimers significantly enhance the binding of the relevant cytokines IFNγ, IL-10 and IFNα Poster #411 Focus: Improved bioactivity for cytokine binding and screening |
| Engineered novel CD4 cis-dimer protein significantly enhances the binding of HIV-1 envelope glycoproteins Poster #2257 Focus: Application in HIV entry models and antibody screening |
| Engineered Nectin-4 and CD155 novel cis-dimer proteins significantly enhance the binding of their receptor TIGIT Poster #2013 Focus: Recombinant tumor associated antigen and checkpoint receptor with enhanced bioactivity |
2025 PEGS Boston Summit
Recombinant G-Protein Coupled Chemokine Receptors CXCR4 and CXCR5 on Nanoparticles are Bioactive, Binding to the Chemokine Ligands |
Engineered Immune Checkpoint CD28 and CTLA-4 Homodimer Proteins Demonstrate Potent Binding Affinities to Their Ligand CD80 |
Engineered Novel CD155 and Nectin-4 Homodimer Proteins Dramatically Enhance Binding Affinities to Their Receptor TIGIT Compared to Respective Monomers |
Novel Soluble Cytokine Receptors IFNγR1 Homodimer and IFNαR1/R2 Heterodimer Enhance Binding to Type II and Type I Interferons Compared to Monomers |
Why It Matters:
Proteins don’t function in isolation — they work within complex biological environments. Our approach focuses on: protein structure isn’t just a feature, it’s the function. These poster presentations provide new data demonstrating how preserving these native conformations can lead to:
- Improved binding potency
- Broader screening windows
- Better tool-molecules for translational immunology
Explore Our Approach: Nature did it first. We make it available.
Conigen recombinant proteins are available as catalog items or as starting points for custom development. Every protein is developed with one goal in mind: creating native-like research tools that move your science forward with greater confidence. View all recombinant proteins here
What’s New at Conigen: Bioactive Recombinant Proteins for Drug Discovery and Antibody Screening
Conigen Bioscience is expanding its portfolio of functional conformational recombinant proteins — designed to mimic native protein structure and function for drug discovery, antibody screening, and translational research.
These recombinant proteins are designed using either the CSP™ (Conigen Soluble Protein) or CMP™ (Conigen Membrane Protein) technology platforms. Each protein is validated to preserve receptor-ligand binding activity and conformational epitopes critical to immune recognition, therapeutic targeting, and lead molecule screening. Some examples include:
- Immune Checkpoint Receptors: CTLA-4, TIGIT, CD28, CD155
- Tumor Associated Antigens: TROP-2, Nectin-4
- Growth Factor Receptors: VEGFR2, FGFR1
- Cytokine Receptors: IFNgR1, IL10Ra, IFNaR1/R2
- T Cell Receptors & Co-Receptors: CD4
- Siglecs: Siglec-6
- B Cell Receptors and Surface Markers: CD19
Why It Matters:
Our approach reflects a simple principle: proteins work best when they look and act the way they do in nature. Conigen’s conformational recombinant proteins offer more reliable tool-molecules for more confident discovery:
- Native-like structures for more physiologically relevant assays
- Higher bioactivity for functional screening and antibody discovery
- Reduced need for re-screening during validation workflows
Explore Our Approach: Nature did it first. We make it available.
Conigen recombinant proteins are available as catalog items or as starting points for custom development. Every protein is developed with one goal in mind: creating native-like research tools that move your science forward with greater confidence.
Download your copy of “Recombinant Conformational Proteins: Novel bioactive soluble dimer and multi-pass membrane proteins to enhance drug discovery”
21st Annual 2025 PEGS Boston Summit
IMMUNOLOGY2025™
May 4-6, 2025
Booth #539
Hawai’i Convention Center
See show details on AAI.org
At AAI 2025 (May 3-7, Honolulu), we’ll showcase our latest innovations in bioactive recombinant membrane proteins—offering new tools for immuno-oncology, inflammation research, and therapeutic discovery.
Discovery starts with the right protein that’s designed for functional binding, better screening and reproducible results!
Meet us in Honolulu—let’s talk about optimizing your experiments!
London Health Sciences Centre
London, Ontario
January 16 | 1:30 PM